Logo image of INCR

INTERCURE LTD (INCR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INCR - IL0011063760 - Common Stock

0.9601 USD
+0.01 (+1.01%)
Last: 1/16/2026, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, INCR scores 3 out of 10 in our fundamental rating. INCR was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of INCR have multiple concerns. INCR is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • INCR had negative earnings in the past year.
  • In the past year INCR has reported a negative cash flow from operations.
  • In multiple years INCR reported negative net income over the last 5 years.
  • In multiple years INCR reported negative operating cash flow during the last 5 years.
INCR Yearly Net Income VS EBIT VS OCF VS FCFINCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

  • With a decent Return On Assets value of -8.62%, INCR is doing good in the industry, outperforming 68.59% of the companies in the same industry.
  • INCR has a Return On Equity of -14.90%. This is in the better half of the industry: INCR outperforms 69.11% of its industry peers.
Industry RankSector Rank
ROA -8.62%
ROE -14.9%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INCR Yearly ROA, ROE, ROICINCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

  • The Gross Margin of INCR (14.90%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of INCR has declined.
  • The Profit Margin and Operating Margin are not available for INCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.13%
GM growth 5Y-1.98%
INCR Yearly Profit, Operating, Gross MarginsINCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

  • INCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • INCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INCR Yearly Shares OutstandingINCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
INCR Yearly Total Debt VS Total AssetsINCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

2.2 Solvency

  • INCR has an Altman-Z score of 0.36. This is a bad value and indicates that INCR is not financially healthy and even has some risk of bankruptcy.
  • INCR has a Altman-Z score (0.36) which is in line with its industry peers.
  • INCR has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.23, INCR perfoms like the industry average, outperforming 43.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 0.36
ROIC/WACCN/A
WACC13.75%
INCR Yearly LT Debt VS Equity VS FCFINCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

  • A Current Ratio of 1.85 indicates that INCR should not have too much problems paying its short term obligations.
  • The Current ratio of INCR (1.85) is worse than 63.87% of its industry peers.
  • A Quick Ratio of 1.39 indicates that INCR should not have too much problems paying its short term obligations.
  • INCR has a Quick ratio of 1.39. This is in the lower half of the industry: INCR underperforms 67.02% of its industry peers.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.39
INCR Yearly Current Assets VS Current LiabilitesINCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

  • INCR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.71%.
  • Looking at the last year, INCR shows a very negative growth in Revenue. The Revenue has decreased by -32.82% in the last year.
  • Measured over the past years, INCR shows a very strong growth in Revenue. The Revenue has been growing by 92.97% on average per year.
EPS 1Y (TTM)-8.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-822.04%
Revenue 1Y (TTM)-32.82%
Revenue growth 3Y2.83%
Revenue growth 5Y92.97%
Sales Q2Q%236.68%

3.2 Future

  • Based on estimates for the next years, INCR will show a very strong growth in Earnings Per Share. The EPS will grow by 561.44% on average per year.
  • INCR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.52% yearly.
EPS Next Y1550%
EPS Next 2Y561.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year39.3%
Revenue Next 2Y40.52%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
INCR Yearly Revenue VS EstimatesINCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M 500M
INCR Yearly EPS VS EstimatesINCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 0.5 1 1.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

  • INCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 5.11, which indicates a rather cheap valuation of INCR.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of INCR indicates a rather cheap valuation: INCR is cheaper than 95.81% of the companies listed in the same industry.
  • INCR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.29.
Industry RankSector Rank
PE N/A
Fwd PE 5.11
INCR Price Earnings VS Forward Price EarningsINCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INCR Per share dataINCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as INCR's earnings are expected to grow with 561.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y561.44%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for INCR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INTERCURE LTD

NASDAQ:INCR (1/16/2026, 8:00:02 PM)

0.9601

+0.01 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-28
Earnings (Next)04-29
Inst Owners3.89%
Inst Owner Change0%
Ins Owners26.05%
Ins Owner Change0%
Market Cap52.50M
Revenue(TTM)238.84M
Net Income(TTM)-67.80M
Analysts82.86
Price TargetN/A
Short Float %0.03%
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.11
P/S 0.69
P/FCF N/A
P/OCF N/A
P/B 0.36
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)0.19
Fwd EY19.56%
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS1.39
BVpS2.64
TBVpS1.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.62%
ROE -14.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.9%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.13%
GM growth 5Y-1.98%
F-Score2
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.4%
Cap/Sales 2.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.39
Altman-Z 0.36
F-Score2
WACC13.75%
ROIC/WACCN/A
Cap/Depr(3y)73.35%
Cap/Depr(5y)210.09%
Cap/Sales(3y)2.61%
Cap/Sales(5y)9.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-822.04%
EPS Next Y1550%
EPS Next 2Y561.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-32.82%
Revenue growth 3Y2.83%
Revenue growth 5Y92.97%
Sales Q2Q%236.68%
Revenue Next Year39.3%
Revenue Next 2Y40.52%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-255.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year271.63%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.79%
OCF growth 3YN/A
OCF growth 5YN/A

INTERCURE LTD / INCR FAQ

What is the ChartMill fundamental rating of INTERCURE LTD (INCR) stock?

ChartMill assigns a fundamental rating of 3 / 10 to INCR.


Can you provide the valuation status for INTERCURE LTD?

ChartMill assigns a valuation rating of 4 / 10 to INTERCURE LTD (INCR). This can be considered as Fairly Valued.


Can you provide the profitability details for INTERCURE LTD?

INTERCURE LTD (INCR) has a profitability rating of 2 / 10.


What is the financial health of INTERCURE LTD (INCR) stock?

The financial health rating of INTERCURE LTD (INCR) is 2 / 10.